0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Relation of Increased Arterial Blood Pressure to Mortality and Stroke in the Context of Contemporary Thrombolytic Therapy for Acute Myocardial Infarction: A Randomized Trial

Philip E. Aylward, BM, BCh; Robert G. Wilcox, MD; John H. Horgan, MD; Harvey D. White, MB, DSc; Christopher B. Granger, MD; Robert M. Califf, MD; and Eric J. Topol, MD,
[+] Article and Author Information

For the GUSTO-I Investigators; Acknowledgments: The authors thank Amanda Stebbins for statistical support and Pat Williams for editorial assistance. Grant Support: In part by Bayer (New York, New York), CIBA-Corning (Medfield, Massachusetts), Genentech (South San Francisco, California), ICI Pharmaceuticals (Wilmington, Delaware), and Sanofi Pharmaccuticals (Paris, France). Requests for Reprints: Robert M. Califf, MD, Box 31123, Duke University Medical Center, Durham, NC 27710. Current Author Addresses: Dr. Aylward: Flinders Medical Centre, Flinders Drive, Bedford Park, South Australia 5042, Australia.


Copyright ©2004 by the American College of Physicians


Ann Intern Med. 1996;125(11):891-900. doi:10.7326/0003-4819-125-11-199612010-00004
Text Size: A A A

Background: Despite concern that hypertension increases the risk for intracranial hemorrhage during thrombolysis for acute myocardial infarction, the exact nature of the risk remains unclear.

Objective: To assess the effects of previous hypertension and blood pressure at study entry on the outcomes of patients who had acute myocardial infarction and received thrombolysis.

Design: Randomized trial.

Setting: 1081 hospitals in 15 countries.

Patients: 41 021 patients who had myocardial infarction accompanied by ST-segment elevation and who presented to hospitals within 6 hours of symptom onset.

Intervention: One of four thrombolytic regimens.

Main Outcome Measures: Mortality, stroke subtypes, and death plus disabling stroke in patients with previous hypertension and as functions of blood pressure at entry. Logistic regression analysis of relations among blood pressure at entry, baseline characteristics, and treatment effects.

Results: The incidence of total stroke and intracranial hemorrhage increased as systolic blood pressure at entry increased and was particularly high for systolic pressures of about 175 mm Hg or more (incidence of total stroke, 3.4% compared with 1.17% for pressures between 100 and 124 mm Hg). Patients who had systolic blood pressure of 175 mm Hg or more at entry and who received accelerated alteplase therapy had a lower rate of death within 30 days (4.3% compared with 7.8%; P = 0.044) and a lower rate of death plus disabling stroke (4.9% compared with 8.9%; P = 0.031) than patients treated with streptokinase, despite having higher rates of total and hemorrhagic stroke (incidence of hemorrhagic stroke, 2.3% compared with 1.5%). Assumptions based on previous trials and rates of stroke from the GUSTO-I (Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries) trial suggest that in hypertensive patients with low risk for death from cardiac causes (no previous infarction, Killip class I), the risk-to-benefit ratio with thrombolysis is about unity, with about 13 lives saved per 1000 persons treated at the risk of about 13 intracranial hemorrhages.

Conclusions: Patients with myocardial infarction and very elevated blood pressure who have thrombolysis and patients with myocardial infarction who do not have elevated blood pressure have a similar risk for death, but the risk for stroke is higher in the former group. Future studies should assess 1) the risk-to-benefit ratio of thrombolysis in these patients, especially those at low risk for death from cardiac causes, and 2) whether decreasing elevated blood pressure before thrombolysis reduces the incidence of stroke without increasing mortality rates.

Figures

Grahic Jump Location
Figure 2. For a comparison of the effect of accelerated alteplase with that of streptokinase after adjustment for systolic blood pressure, = 0.002, 0.083, and 0.01, respectively.
Predicted probabilities with 95% Cls for death within 30 days (top), intracranial hemorrhage (middle), and death plus disabling stroke within 30 days (bottom) by regression analysis as functions of systolic blood pressure at study entry and treatment assignment; accelerated alteplase (solid lines) and the streptokinase monotherapies combined (dashed lines).P
Grahic Jump Location
Grahic Jump Location
Figure 1. < 0.001 for the effect of systolic blood pressure for each end point.
Predicted probabilities (solid lines) with 95% Cls (dashed lines) for death within 30 days (top), intracranial hemorrhage (middle), and death plus disabling stroke within 30 days (bottom) by regression analysis as functions of systolic blood pressure at study entry. P
Grahic Jump Location

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)